A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC
Part of paid clinical trials in Colorado Springs, Colorado.
- Sponsor
- Bristol-Myers Squibb
- Study ID
- NCT03215706
- Phase
- PHASE3
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Ipilimumab — BIOLOGICALSpecified dose on specified day
- Nivolumab — BIOLOGICALSpecified dose on specified day
- Carboplatin — DRUGSpecified dose on specified day
- Paclitaxel — DRUGSpecified dose on specified day
- Pemetrexed — DRUGSpecified dose on specified day
- Cisplatin — DRUGSpecified dose on specified day
Study Details
The purpose of this study is to determine whether Nivolumab, Ipilimumab combined with chemotherapy is more effective than chemotherapy by itself when treating stage IV NSCLC as the first treatment given for the disease
Key Dates
- Start date
- Aug 24, 2017
- Status verified
- Dec 2025
- Primary completion
- Aug 16, 2019
- Completion
- Oct 18, 2024
Study Design
- Enrollment
- 719 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Module AChemotherapy/Biologics combined
- Active Comparator: Module BChemotherapy Combination
Primary Outcome Measure
Overall Survival (OS) [ Time Frame: From date of randomization to date of death (assessed up to October 2019, approximately 23 months) ]
Locations (16)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Memorial Health Systems | Colorado Springs | Colorado | 80909 | - |
| Local Institution - 0044 | Plainville | Connecticut | 06062 | - |
| Local Institution - 0045 | Jacksonville | Florida | 32207 | - |
| Local Institution - 0029 | Marietta | Georgia | 30060 | - |
| Local Institution - 0091 | Wichita | Kansas | 67214 | - |
| Local Institution - 0004 | Lexington | Kentucky | 40503 | - |
| Local Institution - 0105 | Detroit | Michigan | 48202 | - |
| Local Institution - 0058 | Johnson City | New York | 13790 | - |
| Local Institution - 0098 | Mineola | New York | 11501 | - |
| Local Institution - 0095 | Columbus | Ohio | 43210 | - |
| Local Institution - 0006 | Lancaster | Pennsylvania | 17602 | - |
| Local Institution - 0047 | Pittsburgh | Pennsylvania | 15213 | - |
| Local Institution - 0093 | Pittsburgh | Pennsylvania | 15224 | - |
| Local Institution - 0094 | Charleston | South Carolina | 29414 | - |
| Southwest Regional Cancer Clinic | St. George | Utah | 84770 | - |
| Local Institution - 0099 | Madison | Wisconsin | 53705 | - |
Find similar trials in Colorado Springs, CO
By condition
By specialty
Related Studies
- Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL ActivityPHASE2 · Recruiting · Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey
- JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung CancerPHASE3 · Recruiting · University of Texas Southwestern Medical Center · La Jolla, California
- Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI TherapyRecruiting · University of Colorado, Denver · Aurora, Colorado
- VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or LymphomaPHASE1/PHASE2 · Recruiting · VM Oncology, LLC · Santa Rosa, California